# Run 6 real HTTP/external eval — clinician failure digest

Artifact: `docs/eval/run6_real_external_20260725_120653.json`  
Created: 2026-07-25T12:06:53+00:00  
SUT: `agentic-gate-v2-http`  
External judge: `gpt-5`

Scorecard: **4 PASS / 13 MINOR / 15 FAIL**; routing 100.0%; verbatim 100.0%.

> This is an inspectable strict-judge baseline for clinician calibration, not an authoritative pass/fail verdict. `no_grade_drop` compares against fixture-derived grades and is meaningless until the clinician re-baselines the cases.

> Chunk counts are sums of `snippet_count` values recorded by retrieval trace entries and can include multiple guideline branches or attempts. Zero means retrieval starvation; non-zero separates a reasoning/coverage judgment from a no-evidence transport result.

## Per-case retrieval and grade overview

| Scenario | Turn | Grade | Expected routes | Routed routes | Retrieval chunks |
|---|---:|---|---|---|---:|
| aaa_evolving_context | 1 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 5 |
| aaa_evolving_context | 2 | PASS_WITH_MINOR | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 6 |
| aaa_evolving_context | 3 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 12 |
| adversarial_case_switch_chimera | 1 | PASS_WITH_MINOR | carotid_vertebral | carotid_vertebral | 6 |
| adversarial_case_switch_chimera | 2 | FAIL | carotid_vertebral | carotid_vertebral | 0 |
| adversarial_case_switch_chimera | 3 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 8 |
| adversarial_correction_flip | 1 | PASS | carotid_vertebral | carotid_vertebral | 6 |
| adversarial_correction_flip | 2 | PASS_WITH_MINOR | carotid_vertebral | carotid_vertebral | 10 |
| adversarial_declined_question_persistence | 1 | FAIL | asymptomatic_pad | asymptomatic_pad | 14 |
| adversarial_declined_question_persistence | 2 | FAIL | asymptomatic_pad | asymptomatic_pad | 13 |
| adversarial_declined_question_persistence | 3 | FAIL | asymptomatic_pad | asymptomatic_pad | 7 |
| adversarial_duplicate_delivery | 1 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 1 |
| adversarial_duplicate_delivery | 2 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 0 |
| adversarial_knowledge_interleave | 1 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 6 |
| adversarial_knowledge_interleave | 2 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 4 |
| adversarial_knowledge_interleave | 3 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 7 |
| adversarial_retrieval_trap | 1 | FAIL | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 10 |
| batch_c1_proximal_dvt_simple | 1 | PASS_WITH_MINOR | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 14 |
| batch_c2_brachial_vein_compression | 1 | PASS_WITH_MINOR | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 31 |
| batch_c3_carotid_near_occlusion_criteria | 1 | PASS_WITH_MINOR | carotid_vertebral | carotid_vertebral | 6 |
| batch_f1_clti_aps_warfarin | 1 | PASS | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 38 |
| batch_f2_clti_itp_after_bypass | 1 | FAIL | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 20 |
| batch_f3_aaa_clti_sequencing | 1 | PASS_WITH_MINOR | abdominal_aortic_aneurysm, clti | abdominal_aortic_aneurysm, clti | 54 |
| batch_f4_aaa_clti_sepsis_anticoagulation | 1 | PASS_WITH_MINOR | abdominal_aortic_aneurysm, clti, antithrombotic_therapy | abdominal_aortic_aneurysm, clti, antithrombotic_therapy | 0 |
| batch_f5_urgent_cea_af_recent_gi_bleed | 1 | FAIL | carotid_vertebral, antithrombotic_therapy | carotid_vertebral, antithrombotic_therapy | 15 |
| batch_f6_aps_clti_bypass_vs_amputation | 1 | PASS | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 40 |
| batch_s1_asymptomatic_carotid_stenosis | 1 | PASS_WITH_MINOR | carotid_vertebral | carotid_vertebral | 6 |
| batch_s2_post_vein_bypass_antithrombotics | 1 | PASS_WITH_MINOR | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 14 |
| batch_s3_post_endovascular_antithrombotics_itp | 1 | PASS_WITH_MINOR | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 6 |
| batch_s4_symptomatic_carotid_web | 1 | PASS_WITH_MINOR | carotid_vertebral | carotid_vertebral | 7 |
| batch_s5_iliofemoral_dvt_recent_surgery | 1 | PASS | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 5 |
| batch_s6_urgent_cea_af_apixaban | 1 | PASS_WITH_MINOR | carotid_vertebral, antithrombotic_therapy | carotid_vertebral, antithrombotic_therapy | 27 |

## MINOR / FAIL details

### aaa_evolving_context — turn 1 — FAIL

- Scenario turn: A 74-year-old man has an asymptomatic 5.8 cm abdominal aortic aneurysm discovered on ultrasound. He is an active smoker with hypertension and dyslipidaemia. What management would you recommend?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 5 chunks: **YES**
- Judge labels: `missing_required_facts`, `incorrect_management_recommendation`, `clinical_inaccuracy_wrong_threshold`, `did_not_include_fitness_assessment`, `insufficient_patient_specificity`
- Judge reason: The answer omits required case facts (does not state 74-year-old man, asymptomatic 5.8 cm AAA, active smoker) and does not mention fitness assessment. It also misapplies the size threshold, treating the aneurysm as <55 mm, leading to an incorrect recommendation against repair. The response is not adequately tailored to the patient’s specifics per the rubric.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS 2024, men with an asymptomatic abdominal aortic aneurysm <55 mm are NOT recommended for elective repair. Management should include: (1) strong advice and support to stop smoking; (2) comprehensive cardiovascular risk factor management—specifically strict blood pressure control, statin and antiplatelet therapy, and lifestyle advice including exercise and healthy diet. There is no indication for elective AAA repair at this size threshold in men. Continue surveillance as per local protocol.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Although the aneurysm is approaching operative threshold, guideline recommendations are explicit for men with asymptomatic AAA under 55 mm: do NOT proceed to repair, regardless of comorbidities, unless other complicating factors (not described) are present. The priority is strict cardiovascular risk management and smoking cessation. Regular surveillance is implied but the optimal interval is not specified in the provided guideline text.
~~~~

### aaa_evolving_context — turn 2 — PASS_WITH_MINOR

- Scenario turn: CTA now shows that this is a juxtarenal aneurysm with an inadequate infrarenal neck for standard EVAR. His eGFR is 28 mL/min/1.73 m². How does this change your recommendation?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 6 chunks: **YES**
- Judge labels: `missing_must_include_facts`, `incomplete_fitness_assessment`, `context_carryover_omitted`
- Judge reason: Accurately identifies that standard EVAR is unsuitable for a juxtarenal AAA with an inadequate neck and appropriately discusses OSR vs. FEVAR (with contrast-related renal risk) and the impact of CKD (eGFR 28). However, it omits several must-include contextual facts from the case (74-year-old man, asymptomatic 5.8 cm AAA, active smoker, hypertension, dyslipidaemia) and does not explicitly mention the need for a formal fitness assessment. Core recommendation is appropriate but completeness of required details is lacking.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines recommend that standard EVAR is not suitable for juxtarenal AAA with inadequate infrarenal neck. Instead, open surgical repair (OSR) with the proximal anastomosis placed as close as possible to the renal arteries is the favored open approach. Hybrid repair (visceral/renal bypass and endovascular exclusion) is an option in complex cases, especially extrapolated from thoracoabdominal repairs, though the data regarding outcomes are scarce. Fenestrated EVAR (fEVAR) is an established alternative, with data showing similar mortality to OSR, fewer major complications, but a higher reintervention rate. The guidelines highlight the complexity of management but do not provide a direct recommendation regarding advanced chronic kidney disease or the optimal choice between these complex approaches specifically in this context.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
With no guideline interaction or concrete recommendations on patients with both unfavourable juxtarenal anatomy and advanced CKD, selection between fEVAR, OSR, or hybrid repair requires individualised decision-making. Renal preservation is important given underlying CKD; OSR typically risks perioperative renal injury due to aortic clamping, while fEVAR and hybrid approaches may allow more renal preservation but involve contrast exposure and potential device complexity. The patient's comorbidities, particularly renal function (eGFR 28), increase the risk of perioperative AKI or worsening chronic kidney disease with any modality. There may be local expertise or technical limitations for fEVAR or hybrid repair, and these need to be considered. Cross-specialty discussion (including nephrology and anaesthetics) is prudent. Given the lack of strong evidence for the optimal pathway in patients with significant renal impairment, a heart-team approach and detailed discussion of risks and benefits with the patient is recommended.
~~~~

### aaa_evolving_context — turn 3 — FAIL

- Scenario turn: He also has severe COPD, reduced functional capacity, and significant frailty, but remains independent in basic daily activities. Should he still undergo repair, and how would you choose between open repair, FEVAR, and conservative management?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 12 chunks: **YES**
- Judge labels: `missing_required_facts`, `incorrect_evidence_statement`, `state_carryover_failure`
- Judge reason: The response omits multiple required elements from the scenario (e.g., 74-year-old with 5.8 cm asymptomatic AAA, active smoker, hypertension, dyslipidaemia, juxtarenal anatomy with inadequate infrarenal neck rendering standard EVAR unsuitable, eGFR 28 and contrast-nephropathy caution, explicit fitness assessment). It also asserts that guidelines do not cover the decision context despite expected coverage/partial principles, and it fails to carry forward key prior comorbidities and anatomical details into this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines do not provide specific recommendations or decision criteria regarding the management of juxtarenal abdominal aortic aneurysms in patients with severe COPD, significant frailty, and reduced functional capacity, specifically on whether to proceed with repair (open or FEVAR) versus conservative management. There is explicit acknowledgement of a lack of evidence for this complex subgroup and the decision process is not covered. No recommendations regarding preference for open repair, FEVAR, or conservative management in the presence of comorbidities and frailty are found in the grounded sources.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Given the absence of ESVS-guided recommendations, decision-making must rely on individualized risk assessment. In a patient with severe COPD, reduced functional capacity, and significant frailty (but basic independence), the perioperative mortality risk for open repair is likely to be high and may preclude open surgery for all but the most compelling indications. FEVAR may offer a less invasive alternative if available and anatomically suitable, but frailty and comorbidities could still make even endovascular options high-risk. Conservative management is defensible given the lack of guideline support for intervention in patients with limited reserve. The decision should be multidisciplinary, considering local expertise and patient preference. There remains significant clinical equipoise in this area.
~~~~

### adversarial_case_switch_chimera — turn 1 — PASS_WITH_MINOR

- Scenario turn: A 68-year-old woman had a TIA yesterday and has 75% left carotid stenosis. What should we do?
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 6 chunks: **YES**
- Judge labels: `missing_required_facts`
- Judge reason: Management is guideline-consistent and appropriately addresses recent symptomatic 75% stenosis with expedited CEA vs CAS considerations. However, it does not explicitly restate all required case facts (sex and left-sided laterality), only mentioning age, TIA timing, and stenosis severity.

#### `guideline_grounded_answer` (verbatim)

~~~~text
ESVS guidelines support expedited carotid endarterectomy for recently symptomatic (e.g., TIA yesterday) patients aged 68 with 75% carotid stenosis, provided there are no anatomical features or comorbidities that increase risk for surgery. For patients deemed by the MDT to be at higher risk for endarterectomy due to anatomical features or comorbidities, carotid artery stenting can be considered as an alternative if the 30-day risk of death/stroke is <6%. Best medical therapy is assumed as a baseline measure but not specifically detailed for this scenario in the snippets provided.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The optimal management pathway (CEA vs. CAS) cannot be determined without key information on the patient's fitness, comorbidities, and anatomical features affecting surgical risk. For most symptomatic patients with 75% stenosis and no increased procedural risk, CEA is recommended. However, if the MDT identifies high risk features (medical or anatomical) for endarterectomy, carotid stenting may be preferred. Further information about the patient's specific risks and neck anatomy should be sought before making a final recommendation. Medical management should continue alongside intervention planning.
~~~~

### adversarial_case_switch_chimera — turn 2 — FAIL

- Scenario turn: She is functionally independent and the event was non-disabling.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 0 chunks: **NO**
- Judge labels: `missing_required_facts`, `insufficient_substantive_answer`, `contradicts_expected_coverage`
- Judge reason: The response did not include several required case facts (age, TIA timing, 75% left carotid stenosis). It failed to provide a substantive guideline-based follow-up recommendation despite this being a covered scenario, instead asserting that no guideline-based recommendation could be offered. This contradicts the expected coverage and mode for this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
No ESVS guideline-based recommendation can be offered because no core pathway is covered when both imaging of carotid stenosis and comorbidities/anaesthetic risk are undocumented. ESVS decision-making requires imaging confirmation of a significant carotid lesion and an assessment of procedural risk.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Although the patient's functional independence and a non-disabling event would be consistent with considering carotid intervention per ESVS in the context of confirmed symptomatic high-grade stenosis, in the absence of imaging and comorbidity details, it is not possible to determine branch eligibility. Both are usually prerequisite for initiating guideline-based recommendations (e.g., timing and selection between CEA and CAS versus medical therapy only). Until imaging and comorbidity data are available, no guideline-backed management plan can be provided; these details must be sought immediately as they are essential for further decision-making.
~~~~

### adversarial_case_switch_chimera — turn 3 — FAIL

- Scenario turn: New patient: a 76-year-old man with an asymptomatic 6.0 cm infrarenal AAA. How should he be assessed?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 8 chunks: **YES**
- Judge labels: `missing_required_facts`, `evidence_status_mismatch`
- Judge reason: The response did not explicitly include the required patient facts (76-year-old man; asymptomatic 6.0 cm infrarenal AAA). It also marked evidence coverage as partial, whereas the scenario expected covered. Mode, case linkage, guideline routing, and question count were otherwise appropriate, and no prohibited prior-case details were included.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS 2024, men with an abdominal aortic aneurysm greater than 55 mm should be considered for elective repair (Class IIa, Level C). The guidelines state that men with AAA less than 55 mm are not recommended for elective repair. Assessment should confirm the aneurysm's size, patient fitness for intervention, and anatomical suitability for repair using appropriate imaging.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
While ESVS supports considering elective repair in men with AAA >55 mm, actual management must integrate assessment of fitness for intervention and detailed imaging to confirm suitability for either endovascular or open approaches. Identification of significant comorbidities and patient preference are also critical to decision-making. Without confirmation of these factors, definitive management planning cannot proceed.
~~~~

### adversarial_correction_flip — turn 2 — PASS_WITH_MINOR

- Scenario turn: Correction: the patient is asymptomatic and the stenosis is 50–69%, not 70%.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 10 chunks: **YES**
- Judge labels: `missing_correction_provenance`
- Judge reason: The response correctly updates to asymptomatic 50–69% carotid stenosis and avoids mentioning the prior symptomatic/70% details. It aligns with the expected guideline domain and asks no unnecessary questions. However, it does not explicitly acknowledge or retain the correction provenance in the user-visible answer.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines recommend against prophylactic carotid endarterectomy (CEA) or stenting in patients with an asymptomatic 50–69% carotid stenosis undergoing major non-cardiac surgery. For such patients, statin therapy should not be discontinued prior to surgery, and antithrombotic therapy should be managed based on assessment of thromboembolic and haemorrhagic risk. Consideration should be given to starting or continuing lower dose aspirin (75–325 mg daily), primarily to reduce myocardial infarction and other cardiovascular events in patients with >50% asymptomatic stenosis.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
All relevant ESVS guideline components have been identified for this clinical context. There is no recommendation for carotid intervention in the setting of asymptomatic 50-69% stenosis. Emphasis should be placed on optimal medical therapy: continuing statin therapy and individualizing antithrombotic management according to perioperative risk assessment. The pathway does not change unless new symptoms develop or stenosis becomes more severe.
~~~~

### adversarial_declined_question_persistence — turn 1 — FAIL

- Scenario turn: A patient has intermittent claudication and asks about management.
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Retrieval returned 14 chunks: **YES**
- Judge labels: `missing_expected_question`
- Judge reason: The response did not ask the expected question about current smoking status. It met guideline alignment and included the required fact (intermittent claudication), but omitted the key expected question for this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the 2024 ESVS guidelines, management of intermittent claudication should start with a supervised exercise programme as first-line therapy, as it improves walking distance, quality of life, and functional ability. A stepwise approach is advised: risk factor management, best medical treatment, and exercise therapy should be tried first. Revascularisation may be considered as a second step in compliant patients who continue to have disabling symptoms, but should only be pursued after shared decision making, carefully weighing the severity of symptoms, outcomes from non-invasive therapies, comorbidities, procedural risks, and expected long-term benefits. Patient reported outcome measures and functional tests such as the six-minute walking test are recommended to help guide treatment decisions, characterise severity, and evaluate outcomes.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In most patients with intermittent claudication, non-invasive therapy, particularly a supervised exercise programme, is likely appropriate as the starting point. Thoroughly assessing the patient's functional status, severity of symptoms, and impact on daily life using validated tools will help individualise care and ensure that interventions are tailored to patient preferences and objective need. Revascularisation is reserved for those who remain significantly limited despite optimal exercise and medical therapy, and decisions should be made collaboratively due to uncertain long-term benefit and the need to balance procedural risk.
~~~~

### adversarial_declined_question_persistence — turn 2 — FAIL

- Scenario turn: I decline to discuss smoking status. Please proceed with an explicit assumption.
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Retrieval returned 13 chunks: **YES**
- Judge labels: `missing_required_facts`, `assumption_not_recorded`
- Judge reason: The gate reply did not record an explicit assumption as requested/required and did not explicitly mention intermittent claudication. While it correctly avoided further questions and noted that smoking status was declined, it failed two must-include elements for this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For all patients with suspected or confirmed lower limb peripheral arterial disease, it is recommended to ask about tobacco use and, if applicable, advise to stop smoking due to the risk of atherosclerotic disease progression, major cardiovascular events, and limb events from continued smoking.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Since the patient declines to discuss their smoking status, it is not possible to follow the guideline recommendation that is contingent on their disclosure. In this situation, the guideline does not instruct clinicians how to proceed; therefore, it is reasonable to note the absence of this information in the record and explain that advice was not offered due to the patient's preference. No evidence-based alternative pathway is specified if the patient declines to answer. An assumption about smoking status cannot be made; acting as if the patient is a smoker or non-smoker would be outside the guideline. The risk of disease progression and adverse cardiovascular or limb events remains relevant, and this should be documented and, where appropriate, discussed with the patient within scope of their preferences.
~~~~

### adversarial_declined_question_persistence — turn 3 — FAIL

- Scenario turn: What should follow-up focus on?
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Retrieval returned 7 chunks: **YES**
- Judge labels: `missing_required_facts`, `did_not_record_explicit_assumption`, `state_not_persisted`
- Judge reason: The response did not include the required facts that smoking status was declined and that an explicit assumption was recorded. Although it addressed follow-up for intermittent claudication and did not ask new questions or state the current smoking status, it failed to acknowledge the prior declination and to document the explicit assumption as required by the scenario.

#### `guideline_grounded_answer` (verbatim)

~~~~text
Follow-up should focus on: promoting lifestyle change and continued best medical therapy; ensuring participation in and response to a supervised (or structured) exercise programme as first‑line therapy; monitoring adherence, treatment response and adverse events (including early contact after smoking cessation attempts). Re-assess at 3–6 months to judge compliance and symptom improvement. Use objective monitoring outlined in the guideline schedule: blood tests (eg LDL, HbA1c in diabetics), physical examination (blood pressure, ankle or toe pressures, smoking status, diet), and patient‑reported/functional outcomes. If symptoms are not improved or marginal, obtain vascular imaging (duplex ultrasound, CT angiography or MR angiography) to characterise lesions and consider further interventions. Maintain continuous assessment of quality indicators (survival, functional status, complications, major adverse cardiovascular and limb events).
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
For a patient with intermittent claudication, follow-up visits should prioritise: 1) symptom and functional review (walking distance, pain-free walking) and use of a PROM where practical; 2) verification of engagement with and tolerance of the exercise programme and behavioural support; 3) review and optimisation of cardiovascular risk factor control and smoking cessation (with early contact to support quit attempts); 4) simple objective tests (ankle or toe pressures/ABI) to document limb perfusion trends; 5) targeted blood tests (lipids, HbA1c if diabetic) to monitor medical therapy; 6) low threshold for vascular imaging if there is insufficient symptomatic improvement after the initial 3–6 month period to identify lesions potentially amenable to revascularisation; and 7) documentation of complications and use of quality indicators to guide care. These priorities help identify nonresponders and guide escalation from conservative to invasive management when appropriate.
~~~~

### adversarial_duplicate_delivery — turn 1 — FAIL

- Scenario turn: Message-ID dup-001: CTA shows a 5.9 cm juxtarenal AAA.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 1 chunks: **YES**
- Judge labels: `missing_must_include_fact`, `incorrect_evidence_coverage`, `duplicate_merge_state_missing`
- Judge reason: The response omitted the required fact 'message dup-001 merged once,' incorrectly stated the guideline coverage as not covered despite expected coverage, and did not acknowledge/reflect duplicate message merge handling for the stated Message-ID. It did meet mode and question-count constraints but fails key rubric requirements.

#### `guideline_grounded_answer` (verbatim)

~~~~text
There is no direct coverage in current ESVS guidelines for the management of a 5.9 cm juxtarenal abdominal aortic aneurysm. The supplied ESVS content references aneurysms that extend into the visceral segment in the context of thoracoabdominal aneurysms, but does not address isolated juxtarenal AAA or provide specific recommendations for the scenario presented.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The absence of a specific ESVS guideline on juxtarenal AAAs means management decisions must rely on established vascular surgery principles and multidisciplinary assessment. In general, a 5.9 cm juxtarenal AAA in a suitable surgical candidate would often be considered for elective repair, with attention to the anatomical complexity posed by the proximity to the renal arteries. The choice between open and endovascular approaches would further depend on patient fitness, detailed anatomical assessment, and local expertise. Confirming symptom status, rupture risk factors, and fitness for intervention is critical before definitive planning.
~~~~

### adversarial_duplicate_delivery — turn 2 — FAIL

- Scenario turn: Message-ID dup-001: CTA shows a 5.9 cm juxtarenal AAA.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 0 chunks: **NO**
- Judge labels: `missing_message_merge_ack`, `evidence_status_incorrect`
- Judge reason: Did not include the required deduplication acknowledgment (“message dup-001 merged once”), and incorrectly marked evidence coverage as not covered despite expectation of covered. Other elements (same_case true, mode case_followup_substantive, inclusion of 5.9 cm juxtarenal AAA, ≤2 questions) were acceptable.

#### `guideline_grounded_answer` (verbatim)

~~~~text
No ESVS guidance is available regarding the management of a 5.9 cm juxtarenal abdominal aortic aneurysm. The supplied evidence search found no recommendations for intervention thresholds, symptomatic versus asymptomatic disease, or fitness assessments for juxtarenal anatomy cases.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In current specialist vascular practice, AAA repair (open or endovascular) is generally considered for aneurysms larger than 5.5 cm, or for symptomatic or rapidly expanding aneurysms, provided the patient is fit for intervention. Juxtarenal location complicates both open and endovascular strategies. Key management details therefore hinge on whether the patient is symptomatic (pain, tenderness, embolic phenomena), and whether multidisciplinary assessment finds the patient fit for major vascular intervention. If asymptomatic and unfit, conservative management may be preferred.
~~~~

### adversarial_knowledge_interleave — turn 1 — FAIL

- Scenario turn: A 72-year-old man has an asymptomatic 5.7 cm infrarenal AAA and CKD.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 6 chunks: **YES**
- Judge labels: `missing_required_facts`, `guideline_frame_integrity`
- Judge reason: The response did not include all required case facts: it omitted the patient’s age (72-year-old) and the infrarenal location when restating the problem, which were specified as must-include. Additionally, the guideline-grounded section extended ESVS claims by citing comorbidities such as CKD as a specific indication to consider fitness/anatomy/preferences without clear grounding in the provided guideline context.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the ESVS 2024 guidelines, men with an asymptomatic abdominal aortic aneurysm (AAA) greater than 55 mm (>5.5 cm) should be considered for elective repair (Class IIa, Level C). Patients who have reached the size threshold at which repair is considered (i.e., >5.5 cm in men) should receive a fast-track pathway to vascular surgical care (Class I, Level C). Shared decision making should be facilitated during discussions about management options (Class I, Level B). Consideration of patient fitness, aneurysm anatomy, and patient preferences is recommended if complex anatomy is present or there are comorbidities such as CKD.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The patient meets the ESVS guideline size threshold for consideration of elective repair (5.7 cm in a male, asymptomatic). However, CKD is a significant comorbidity that impacts perioperative risk; full assessment of surgical fitness and renal function is essential before proceeding. The anatomical suitability for repair (e.g., suitability for EVAR vs. open repair given CKD) and explicit patient preferences are not yet detailed. Patient-centered discussion and risk stratification are crucial, particularly concerning renal risk in any intervention.
~~~~

### adversarial_knowledge_interleave — turn 2 — FAIL

- Scenario turn: As a general knowledge question, what diameter threshold does ESVS use in women?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 4 chunks: **YES**
- Judge labels: `missing_required_facts`
- Judge reason: The response did not include the required case facts (72-year-old man, asymptomatic 5.7 cm infrarenal AAA, CKD) despite same_case being true and must_include_facts specifying these details.

#### `guideline_grounded_answer` (verbatim)

~~~~text
ESVS recommends that women with an abdominal aortic aneurysm ≥ 50 mm may be considered for elective repair, and that women with an asymptomatic AAA < 50 mm are not recommended for elective repair.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The 50 mm threshold applies to consideration for elective repair rather than an absolute mandate; clinical decisions should take into account fitness for repair, aneurysm anatomy, and patient preferences. The recommendation is class IIb (level C), indicating limited evidence/consensus. For context, the guideline uses a higher threshold for men (≥ 55 mm) for consideration of repair.
~~~~

### adversarial_knowledge_interleave — turn 3 — FAIL

- Scenario turn: Back to this patient: renal function has worsened. How does that affect planning?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 7 chunks: **YES**
- Judge labels: `missing_required_facts`
- Judge reason: The answer does not include the required case-specific facts (72-year-old man, asymptomatic 5.7 cm infrarenal AAA, CKD, and explicitly that renal function has worsened). It provides generic guidance without restating the mandated patient details, violating the must_include_facts criterion.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the ESVS 2024 guidelines, worsening renal function in a patient being considered for abdominal aortic aneurysm (AAA) repair necessitates:
- Assessment of pre-operative kidney function by measuring serum creatinine and estimated glomerular filtration rate (eGFR), especially if eGFR <30 mL/min/1.73 m2.
- Ensuring adequate hydration prior to elective AAA repair.
- If endovascular repair is undertaken, strategies to preserve renal function should be considered (dose reduction of iodine contrast media, withdrawal of nephrotoxic drugs, and adequate hydration).
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Worsening renal function increases perioperative risks and heightens the importance of renal protective measures, influencing timing and the conduct of AAA repair. All detailed management advice above directly reflects ESVS recommendations; however, specifics such as urgency or selection of open versus endovascular approach will depend on further anatomical and fitness information not yet documented. No further targeted questions are needed at this stage as all guideline-mandated requirements for patients with renal impairment have been addressed in the answer above.
~~~~

### adversarial_retrieval_trap — turn 1 — FAIL

- Scenario turn: A patient has an infrarenal abdominal aortic mural thrombus with distal embolisation. Which ESVS pathway should ground the assessment?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Retrieval returned 10 chunks: **YES**
- Judge labels: `incorrect_pathway_selection`, `evidence_status_nonconforming`, `retrieval_recovery_not_shown`
- Judge reason: Did not ground assessment to the expected ESVS abdominal aorto-iliac aneurysm pathway and instead concluded the topic is not covered. Evidence status marked as not_covered, which is outside allowed statuses (covered/partial_principles/retrieval_uncertain). The response also failed to demonstrate recovery from off-target retrieval as required. While it included the key facts (infrarenal abdominal aortic mural thrombus and distal embolisation) and avoided descending thoracic aorta grounding, these do not offset the primary guideline and retrieval requirements being unmet.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms do not cover the assessment or management of native infrarenal abdominal aortic mural thrombus with distal embolisation. The only discussion of mural thrombus is in the context of patients with stent grafts post-endovascular aneurysm repair, with no recommendations offered for mural thrombus or embolisation in native (non-aneurysm, non-stent graft) aorta. No suitable alternative ESVS pathway is identified in the supplied material.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Given the absence of ESVS recommendations for this scenario, assessment and management should be guided by expert consensus or local protocols. The presence of distal embolisation indicates a potentially unstable source of arterial thrombus, which may warrant further imaging evaluation, consideration of cause (e.g., hypercoagulable state, underlying aortic pathology), and multidisciplinary decision-making regarding medical versus potential interventional management. Vascular MDT input is recommended.
~~~~

### batch_c1_proximal_dvt_simple — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with proximal femoral DVT, no severe symptoms, no cancer, no bleeding risk. Should this patient receive anticoagulation alone, undergo thrombolysis, or have an IVC filter?
- Expected guidelines: venous_thrombosis
- Routed guidelines: venous_thrombosis, antithrombotic_therapy
- Retrieval returned 14 chunks: **YES**
- Judge labels: `F3`
- Judge reason: Core recommendation aligns (anticoagulation alone; no thrombolysis; no IVC filter), but it omits the expected 3‑month DOAC duration and is not in the requested compact format.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, in patients with proximal femoral DVT who have no severe symptoms, no cancer, and no bleeding risk, therapeutic anticoagulation with direct oral anticoagulants (DOACs) is preferred (Class I A). Early thrombus removal (thrombolysis) is reserved for selected patients with symptomatic iliofemoral DVT (Class IIa A) and not generally recommended for patients with only proximal femoral involvement and no severe symptoms. Temporary IVC filter insertion is only recommended if anticoagulation is contraindicated or impossible (Class I B). Thus, the ESVS pathway supports anticoagulation alone as standard management in this scenario.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is no specific ESVS statement on the interaction of these modalities in patients with proximal femoral (as opposed to iliofemoral) DVT who lack severe symptoms or cancer and who have no contraindication to anticoagulation. The guidelines make clear distinctions: thrombolysis is for selected, usually more severe or iliofemoral DVT cases, and IVC filters are reserved for cases where anticoagulation cannot be given. Therefore, based on both principles and the typical clinical reasoning, anticoagulation alone is recommended. Additional risk factors or anatomic extension to the iliac vein, or emergence of severe symptoms, might change this recommendation, but for the presented facts, anticoagulation alone fits both the letter and spirit of ESVS guidance.
~~~~

### batch_c2_brachial_vein_compression — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with tumor compressing the brachial vein. No thrombosis. Symptomatic swelling. Should he take anticoagulation?
- Expected guidelines: venous_thrombosis
- Routed guidelines: venous_thrombosis, antithrombotic_therapy
- Retrieval returned 31 chunks: **YES**
- Judge labels: `F7`, `F3`, `F5`
- Judge reason: Correctly advises against routine anticoagulation without thrombosis, but the response is not in COMPACT mode and omits key adjuncts expected by the rubric: explicitly managing the underlying compression and explicitly monitoring for DVT.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines do not provide a recommendation for or against anticoagulation solely for patients with symptomatic venous compression by a tumor in the absence of thrombosis. Existing recommendations focus on anticoagulation for cancer-associated venous thromboembolism, but no specific guidance was found for management of pure extrinsic compression without confirmed thrombus.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of thrombosis, current ESVS guidance does not support routine anticoagulation for symptomatic swelling due solely to venous compression from a tumor. Anticoagulation is clearly recommended when venous thromboembolism is present; however, when only compression and swelling exist, the lack of an ESVS recommendation suggests anticoagulation is not routinely indicated—unless there are exceptional contextual factors (e.g., high risk for imminent thrombosis judged clinically, or new symptoms develop). Close clinical follow-up and reassessment if clinical status changes is warranted. This management approach is common practice in the absence of clear guidance.
~~~~

### batch_c3_carotid_near_occlusion_criteria — turn 1 — PASS_WITH_MINOR

- Scenario turn: Give the criteria of carotid near-occlusion.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 6 chunks: **YES**
- Judge labels: `F7`
- Judge reason: Includes the key diagnostic elements (definition, severe proximal stenosis, distal ICA collapse, and comparison to the contralateral side), but adds unnecessary management/practical considerations and is not as compact as requested.

#### `guideline_grounded_answer` (verbatim)

~~~~text

~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Carotid near-occlusion is a pathophysiologic and imaging diagnosis characterized by an almost-occluding high-grade stenosis of the proximal internal carotid artery (ICA) with secondary reduction in the calibre and flow in the distal ICA rather than a simple focal high-grade stenosis with preserved downstream lumen. Key, commonly used diagnostic features are: 

- Severe narrowing of the proximal ICA with a markedly reduced distal ICA lumen compared with the contralateral ICA (distal vessel ‘collapse’ or thread-like appearance).
- Persistence of some antegrade flow or contrast passage beyond the stenotic segment (distinguishes near-occlusion from complete occlusion).
- Two recognized patterns: partial collapse (distal ICA reduced but visible and more normal-calibre branches) and full/total collapse (very small, thread-like distal ICA). 
- Imaging correlates:
  - Digital subtraction angiography / CTA: marked proximal stenosis with markedly reduced distal ICA calibre and delayed contrast opacification; ‘string sign’ appearance in severe cases.
  - Duplex ultrasound: very high flow velocities at the stenosis may be seen, but distal ICA calibre is reduced and flow signals distal to the lesion are diminished; interpretation requires correlation with cross-sectional imaging because velocities alone can be misleading.
  - Perfusion/CT timing: delayed transit in the ipsilateral circulation and collateral patterns may be present.

Practical points: differentiate near-occlusion from complete occlusion (some distal lumen/flow present in near-occlusion) and from high-grade stenosis without distal collapse (distal ICA calibre preserved). Imaging should be assessed in multiple projections/modalities to confirm distal collapse. Clinically, near-occlusion has different natural history and treatment considerations than standard high-grade stenosis; decisions about intervention typically require multidisciplinary review and consideration of symptoms and response to best medical therapy.
~~~~

### batch_f2_clti_itp_after_bypass — turn 1 — FAIL

- Scenario turn: Post-op management of CLTI patient with ITP submitted to bypass surgery.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Retrieval returned 20 chunks: **YES**
- Judge labels: `F2`, `F6`
- Judge reason: The answer acknowledges post-operative CLTI with ITP after bypass and notes that ITP may alter standard therapy, and it suggests potential deferral/titration (stepwise/delayed escalation). However, it omits the core recommendation to use standard aspirin plus rivaroxaban when bleeding risk is acceptable, and it does not explicitly anchor management to platelet count/bleeding status or ask for these details in the final response. These gaps miss key elements of the rubric’s core answer and expected questioning.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For patients with chronic limb threatening ischaemia (CLTI) who have undergone lower extremity vein bypass, the ESVS guideline (Global Vascular Guidelines on CLTI Management) recommends regular clinical surveillance for at least 2 years. This program should include interval history, pulse examination, measurement of resting ankle pressures and toe pressures, with possible use of duplex ultrasound scanning where available. The guideline does NOT address postoperative antithrombotic or antiplatelet management in the specific context of idiopathic thrombocytopenic purpura (ITP), nor does it offer management integration for this comorbidity.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is a significant management gap when CLTI coexists with ITP, as the haemorrhagic risk may preclude or modify standard post-bypass antithrombotic protocols. In actual practice, individualized balancing of bleeding and thrombosis risks is necessary, often requiring input from a haemostasis or haematology specialist. In such cases, maximizing surveillance as per ESVS principles becomes even more crucial, and standard antithrombotic initiation may need to be deferred or carefully titrated according to ITP severity and haematology advice. This approach is based on consensus and expert opinion owing to the lack of specific ESVS guidance for CLTI post-bypass with ITP.
~~~~

### batch_f3_aaa_clti_sequencing — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with a 5.8 cm infrarenal AAA and concomitant CLTI (Rutherford 5, tissue loss). Which should be treated first — aneurysm repair or limb revascularisation? Clarifications: asymptomatic AAA, stable.
- Expected guidelines: abdominal_aortic_aneurysm, clti
- Routed guidelines: abdominal_aortic_aneurysm, clti
- Retrieval returned 54 chunks: **YES**
- Judge labels: `F6`
- Judge reason: Meets core expectations: acknowledges both conditions are guideline-covered individually, states there is no ESVS sequencing rule, and indicates limb revascularisation is usually prioritised first in this context. Includes all key case facts. Minor issue: does not make an explicit sequencing decision as requested, framing it as general practice/clinical judgment rather than a clear recommendation.

#### `guideline_grounded_answer` (verbatim)

~~~~text
There is no direct ESVS guidance on the sequencing of intervention (limb versus aneurysm) in patients with a stable, asymptomatic infrarenal abdominal aortic aneurysm (AAA) and chronic limb-threatening ischemia (CLTI) with tissue loss. The CLTI guidance recommends revascularisation for advanced limb threat but does not address comorbidity with AAA. Likewise, the AAA guideline does not specify prioritisation in patients with concurrent CLTI.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of guideline coverage, sequencing should be determined by clinical judgement. For a stable, asymptomatic 5.8 cm infrarenal AAA, the immediate risk of rupture is present but not necessarily critical. In contrast, Rutherford 5 CLTI (with tissue loss) carries significant risk of limb loss and morbidity if not revascularised. In practice, many surgeons prioritise limb salvage unless the aneurysm is symptomatic or judged imminently at risk of rupture. Planning should account for patient-specific risk (including perioperative risk and anatomy for both AAA and limb disease), and consider combined or staged intervention if feasible in selected patients.
~~~~

### batch_f4_aaa_clti_sepsis_anticoagulation — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with 6.5 cm infrarenal AAA and concomitant CLTI (Rutherford 6, wet gangrene with sepsis) on rivaroxaban for AF. Should you prioritise aneurysm repair, limb surgery, or infection control first? How should anticoagulation and antiplatelet therapy be managed perioperatively? Clarifications: AAA asymptomatic, stable.
- Expected guidelines: abdominal_aortic_aneurysm, clti, antithrombotic_therapy
- Routed guidelines: abdominal_aortic_aneurysm, clti, antithrombotic_therapy
- Retrieval returned 0 chunks: **NO**
- Judge labels: `F2`, `F6`
- Judge reason: Correctly prioritizes infection/source control first and limb surgery before AAA repair given a stable, asymptomatic 6.5 cm AAA. Appropriately advises holding rivaroxaban perioperatively. However, it fails to state the expected ‘no routine bridging for standard AF’ and does not clearly specify restart timing once haemostasis/infection control allow, leading to minor deviations from the core expected answer.

#### `guideline_grounded_answer` (verbatim)

~~~~text
There is no direct ESVS guideline recommendation on the prioritisation of interventions (aneurysm repair vs limb surgery vs infection control) in a patient with an asymptomatic, stable, large infrarenal AAA and concomitant CLTI (wet gangrene with sepsis), nor on the specific perioperative management of rivaroxaban and antiplatelet therapy in this context.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of ESVS guideline direction, clinical reasoning dictates that in a patient with wet gangrene and sepsis (Rutherford 6 CLTI) and a stable, asymptomatic 6.5 cm infrarenal AAA, infection control is the immediate priority. Sepsis due to wet gangrene carries a high risk of mortality if untreated and may preclude delayed intervention. Thus, urgent source control via amputation or debridement should precede aneurysm repair unless there are signs of impending aneurysm rupture. Anticoagulation with rivaroxaban should be held perioperatively for surgical intervention due to bleeding risk, and bridging should be considered according to general perioperative AF guidelines (not specified in ESVS). Antiplatelet therapy can be reassessed after the acute event; its use is not directly addressed by the ESVS guidelines provided.
~~~~

### batch_f5_urgent_cea_af_recent_gi_bleed — turn 1 — FAIL

- Scenario turn: 75-year-old with TIA 2 days ago, 80% symptomatic carotid stenosis, AF on apixaban, recent upper GI bleed 7 days ago now stable. Proceed to urgent CEA or delay? How should apixaban and antiplatelet therapy be managed?
- Expected guidelines: carotid_vertebral, antithrombotic_therapy
- Routed guidelines: carotid_vertebral, antithrombotic_therapy
- Retrieval returned 15 chunks: **YES**
- Judge labels: `F2`, `F3`, `F6`, `F7`
- Judge reason: The response does not clearly recommend urgent CEA within days, gives no explicit plan to stop apixaban without bridging, lacks a bleeding-modified antiplatelet strategy, and does not caution against triple therapy. It emphasizes guideline gaps and defers to multidisciplinary discussion rather than delivering the required concrete management steps.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For patients with recently symptomatic 50–99% carotid stenosis scheduled for carotid endarterectomy (CEA), antiplatelet therapy is recommended throughout the peri-operative period and long term. Peri-operative dual antiplatelet therapy (DAPT: aspirin plus clopidogrel) may be considered and started after imaging has excluded intracranial haemorrhage (Class IIa, Level C). Gastric protection (PPI, e.g., pantoprazole) should be considered for individuals at elevated risk for gastrointestinal bleeding. There are no ESVS recommendations in the supplied snippets on management of perioperative anticoagulation (apixaban) or the precise timing of CEA in patients with recent GI bleeding and concurrent atrial fibrillation.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The ESVS guidelines support urgent CEA after recent TIA and severe symptomatic carotid stenosis, but do not provide specific direction for perioperative anticoagulation in patients with a recent GI bleed. In the case of recent upper GI bleeding now stable, the risk of recurrent neurological events if surgery is delayed must be balanced against the risk of recurrent or perioperative GI bleeding and the risk of perioperative stroke with suboptimal antithrombotic management. There is also no direct ESVS guidance on when to restart or interrupt apixaban in this high-risk setting, nor on the interaction of DAPT and anticoagulation following recent GI bleeding. Multidisciplinary consultation (vascular surgery, neurology/stroke, gastroenterology, haematology) is strongly advised. Expert management would typically individualize timing of CEA and intensity of antithrombotic therapy balancing bleeding and thromboembolic risks, often prioritizing stabilization of GI pathology and minimizing total antithrombotic burden perioperatively, but definitive guidance is absent from ESVS.
~~~~

### batch_s1_asymptomatic_carotid_stenosis — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with asymptomatic carotid stenosis 75%, age 72, on best medical therapy, no prior stroke/TIA, unilateral disease, CTA confirmed, low surgical risk. Should this patient undergo CEA, CAS, or medical therapy only?
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 6 chunks: **YES**
- Judge labels: `F5`
- Judge reason: The answer aligns with the expected core: continue best medical therapy with no routine intervention; CEA only in selected high-risk-feature cases; CAS only if CEA unsuitable. Minor issues include referencing an unrelated ESVS recommendation (post-stenting restenosis) and hedging about lack of direct guideline text rather than providing a clear, guideline-grounded statement for the primary asymptomatic case.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For patients with asymptomatic re-stenosis >70% after carotid stenting, ESVS recommends medical management. However, no direct ESVS recommendation was located regarding intervention (CEA or CAS) versus medical therapy only for patients with primary (not post-stenting) asymptomatic carotid stenosis of 75%, aged 72, on best medical therapy, low surgical risk, and no prior stroke/TIA. Guidance documents highlight that most asymptomatic patients, even with high-grade stenosis, gain little benefit regarding late stroke prevention from intervention compared to optimized medical therapy, particularly if surgical/death risk is not well below 3%. Population screening and intervention are not recommended outside of selected patient groups, especially given current low procedural benefit.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The ESVS guidelines do not provide a directly applicable recommendation for this patient scenario. They support medical management for asymptomatic >70% restenosis after stenting, and argue that even in high surgical candidates with primary asymptomatic carotid stenosis, the net benefit of CEA or CAS is small unless individual patient risk is very high or procedural risks are unusually low. Given age 72, 75% unilateral stenosis, absence of prior neurological events, and low surgical risk, the default expert approach would be to continue best medical therapy unless additional high-risk features (e.g., rapidly progressing stenosis, evidence of plaque instability, or other risk modifiers unlisted here) are present. CAS is generally reserved for patients unsuitable for CEA. The decision should be individualized, but current ESVS evidence weighs against routine intervention in such patients.
~~~~

### batch_s2_post_vein_bypass_antithrombotics — turn 1 — PASS_WITH_MINOR

- Scenario turn: What is the recommended antithrombotic therapy after lower limb revascularization for peripheral arterial disease? Clarifications: vein BK bypass, rest pain pre-op, no high bleeding risk.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Retrieval returned 14 chunks: **YES**
- Judge labels: `F3`
- Judge reason: The answer correctly recommends aspirin plus low-dose rivaroxaban for an infrainguinal autologous vein below-knee bypass without high bleeding risk and acknowledges the patient context. However, it omits two rubric elements: advising against prolonged clopidogrel beyond 30 days and noting single antiplatelet therapy as an alternative when appropriate.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the ESVS 2023 guideline (Class IIa, Level B), for patients undergoing lower limb infrainguinal bypass with autologous vein (such as a below knee vein bypass) and who are not at high bleeding risk, it is recommended to consider aspirin (75–100 mg once daily) in combination with rivaroxaban (2.5 mg twice daily) to reduce the risk of secondary cardiovascular and major adverse limb events.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The current patient facts align closely with the discriminating variables in the guideline pathways: autologous vein conduit and absence of high bleeding risk. Although the guideline is based on general recommendations after infrainguinal bypass, and the evidence basis (Bonaca et al., Debus et al.) includes but does not single out below-knee bypass for rest pain, no further clinical details appear to alter the branch choice given the explicit alignment specified. Thus, the combination of aspirin and low-dose rivaroxaban is the evidence-based recommendation for this scenario, and there are no missing variables that would plausibly switch this patient to single antiplatelet therapy or another alternative.
~~~~

### batch_s3_post_endovascular_antithrombotics_itp — turn 1 — PASS_WITH_MINOR

- Scenario turn: What is the recommended antithrombotic therapy after lower limb revascularization for peripheral arterial disease? Clarifications: endovascular tibial angioplasty DEB, symptomatic IC/CLTI, ITP.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Retrieval returned 6 chunks: **YES**
- Judge labels: `F2`, `F7`
- Judge reason: Addresses PAD post-endovascular context, acknowledges ITP as a bleeding modifier, and highlights need to minimize therapy and involve hematology. However, it does not clearly state the standard post-procedure options (aspirin plus low-dose rivaroxaban or short-course DAPT) and omits an explicit mention of short-course DAPT. It also does not explicitly ask the key clarifying questions about current platelet count and active bleeding status.

#### `guideline_grounded_answer` (verbatim)

~~~~text
From the retrieved ESVS material: (1) In the rare post-revascularisation scenario where triple antithrombotic therapy is deemed necessary after endovascular intervention in intermittent claudication, patients receiving aspirin plus low‑dose rivaroxaban should not continue clopidogrel beyond 30 days because bleeding risk likely outweighs benefit. (2) For patients with chronic PAD who have an independent clinical indication for full‑dose anticoagulation, routine addition of antiplatelet therapy is not recommended.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Application to this patient (tibial DEB for symptomatic IC/CLTI with ITP) requires individualized judgement and additional clinical data (notably current platelet count, bleeding history and indication strength for anticoagulation). Key practical points: - The ESVS guidance flags short duration of clopidogrel if combining aspirin+low‑dose rivaroxaban, and warns against adding antiplatelet to full‑dose anticoagulation routinely. - In immune thrombocytopenic purpura (ITP) the bleeding risk and platelet availability may substantially change the balance; consult haematology. - Aim to minimise combined antithrombotic exposure (use the least intensive effective regimen for the shortest necessary duration). - If a clinician is considering any form of triple therapy or adding anticoagulation, use multidisciplinary discussion (vascular, haematology) to weigh limb/ischemic risk versus bleeding and to decide duration and monitoring. Given missing patient-specific details (current platelet count, bleeding history, whether full‑dose anticoagulation is otherwise indicated), recommend escalation for a patient-specific management plan.
~~~~

### batch_s4_symptomatic_carotid_web — turn 1 — PASS_WITH_MINOR

- Scenario turn: How to treat symptomatic carotid web in a 40-year-old patient? Clarifications: symptoms 1 week ago, 70% stenosis, no prior history.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Retrieval returned 7 chunks: **YES**
- Judge labels: `OMITTED_PATIENT_FACTS`
- Judge reason: Meets core rubric: offers revascularisation, indicates CEA preference in a young fit patient absent contraindications, and acknowledges limited/IIb-level support. Minor omissions: does not explicitly restate the provided timing (one week) or the absence of prior history in the final answer. Content-gap handled appropriately with principled framing.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For a 40-year-old patient with a symptomatic carotid web and 70% stenosis, ESVS guidelines state that carotid endarterectomy or carotid artery stenting may be considered to prevent recurrent stroke, provided no other cause for stroke is identified after detailed neurovascular work-up (Class IIb, Level C). Additionally, for symptomatic patients with 70–99% carotid stenosis, carotid endarterectomy is recommended if the 30-day risk of death/stroke is <6%.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The decision between carotid endarterectomy (CEA) and carotid artery stenting (CAS) may be guided by anatomical considerations, comorbidities, patient fitness, and procedural risk, none of which are detailed for this patient. In young, otherwise healthy patients, CEA is frequently the preferred first-line intervention, assuming no contraindications. However, a multidisciplinary discussion is appropriate, especially given the rarity and evolving evidence base around carotid web as a stroke mechanism. A high-quality neurovascular workup should confirm absence of alternative stroke causes before intervention.
~~~~

### batch_s6_urgent_cea_af_apixaban — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with symptomatic carotid stenosis (80%) scheduled for urgent CEA is found to have AF on apixaban. Recent TIA 10 days ago. Persistent AF. How should anticoagulation be managed perioperatively, and should antiplatelet therapy be added?
- Expected guidelines: carotid_vertebral, antithrombotic_therapy
- Routed guidelines: carotid_vertebral, antithrombotic_therapy
- Retrieval returned 27 chunks: **YES**
- Judge labels: `F2`
- Judge reason: Covers antiplatelet use for CEA and suggests perioperative DOAC interruption with postoperative resumption, and cautions about bleeding with combination therapy. However, it does not clearly affirm that CEA remains urgent in this scheduled case, introduces ambiguity by suggesting MDT may choose anticoagulation alone, and does not explicitly state no routine bridging for AF. It also lacks a clear directive to avoid prolonged combination strategies after surgery.

#### `guideline_grounded_answer` (verbatim)

~~~~text
1. All recently symptomatic carotid stenosis patients undergoing CEA should be prescribed antiplatelet therapy perioperatively and long-term (Class I, Level A), but local protocols (neurologists/stroke physicians and vascular surgeons) should specify regimen (combination therapy vs. monotherapy) and avoid delaying surgery (Class I, Level C). 
2. Peri-operative combination antiplatelet therapy (aspirin plus clopidogrel) should be considered in recently symptomatic patients with 50–99% carotid stenosis who are to undergo CEA, and should be started only after imaging has excluded intracranial haemorrhage (Class IIa, Level C). 
3. In patients presenting with TIA or minor stroke plus known or newly diagnosed AF and ipsilateral 50–99% carotid stenosis, comprehensive neurovascular workup and multidisciplinary team review are recommended to determine whether urgent revascularization or anticoagulation alone is indicated (Class I, Level C). 
4. There is no explicit ESVS guidance in the supplied snippets on how to manage perioperative anticoagulation (DOAC interruption/bridging) or its combination with antiplatelet agents for patients with persistent AF undergoing CEA; nor is the interaction covered for combined use of DOAC and antiplatelet therapy in the perioperative phase.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The guidelines clearly state all patients in this scenario should receive perioperative and long-term antiplatelet therapy, with combination therapy (aspirin + clopidogrel) to be considered after intracranial haemorrhage is excluded. However, they do not comment on the management of ongoing anticoagulation (apixaban) or its interaction with antiplatelet therapy, which is directly relevant for this AF patient. Expert practice, absent ESVS guidance, is to hold DOAC preoperatively according to renal function and bleeding risk, then restart DOAC postoperatively when haemostasis is secured. The addition of perioperative DAPT to anticoagulation, however, is associated with excess bleeding risk and is not directly supported by guideline evidence here; in practice, many MDTs would individualize, potentially using SAPT perioperatively, and coordinate timing and overlap carefully. For this patient, the antithrombotic approach (type, combination, timing) should be finalized in consultation with neurology/stroke, anesthesia, and vascular surgery, considering both stroke and bleeding risks. The lack of branch-bridging ESVS evidence means the MDT should drive final perioperative antithrombotic sequencing here.
~~~~

